Yuhan Corporation Q3 Operating Profit Up 54% YoY... Sales Increase 10.5%

Yuhan Corporation announced on the 31st that its standalone operating profit for the third quarter of this year was preliminarily estimated at 6.889 billion KRW, a 53.7% increase compared to the same period last year.

Exterior view of Yuhan Corporation headquarters.
[Photo by Yuhan Corporation]

During the same period, sales revenue increased by 10.5% to 468.89 billion KRW, and net profit rose by 129.5% to 12.822 billion KRW.

Looking at the consolidated results, sales revenue was recorded at 483.063 billion KRW, up 11.9% from the same period last year, and operating profit turned positive at 883 million KRW.

Examining the performance by business division, the pharmaceutical division posted sales of 346.182 billion KRW, a 2.1% increase compared to the same period last year. Prescription drugs recorded sales of 299.261 billion KRW, up 4.4% from the previous year, while over-the-counter drugs generated sales of 46.921 billion KRW, a 10.5% decrease.

Looking at sales by major products on a cumulative basis for the third quarter, the dyslipidemia treatment 'Rosuvamib' saw sales grow 49.6% year-on-year to 58.195 billion KRW. The diabetes treatment 'Jardiance' (30.7%), the nutritional supplement 'Magbi' (28%), and the human immunodeficiency virus (HIV) treatment 'Viktavi' (26.4%) also posted solid sales.

Among other divisions, the lifestyle distribution division showed significant growth. Third-quarter lifestyle distribution sales reached 59.521 billion KRW, a 71.3% increase compared to the same period last year. During the same period, overseas business sales rose 33.5% to 58.587 billion KRW. In contrast, license revenue sales sharply declined by 83.9% year-on-year to 510 million KRW.

This content was produced with the assistance of AI translation services.